Clorox Reports Q4 and FY26 Results, Provides FY27 Outlook

Clorox's profits and cash flow fell sharply despite the GOJO acquisition boost.

What the company is saying

Clorox presents its fourth quarter and fiscal year 2026 results by highlighting net sales figures, the completed GOJO acquisition, and its impact on reported sales. The company quantifies the GOJO acquisition's contribution—about 10 points to Q4 net sales and 3 points to full-year net sales—while acknowledging organic sales declines and margin compression. The narrative is framed around operational challenges, including ERP transition impacts and cost headwinds, but emphasizes the expanded health and hygiene portfolio now comprising more than half of net sales. Leadership, specifically Chair and CEO Linda Rendle and CFO Luc Bellet, are named but not used as credibility anchors for forward-looking claims. The tone is neutral, with no attempt to reframe negative results as positive or to use promotional language. The announcement emphasizes transparency in headline metrics but omits specific acquisition costs, capital expenditures, and geographic sales breakdowns.

What the data suggests

The numbers show a clear deterioration in Clorox's financial performance. Q4 net sales fell 2% to $1.95 billion, and full-year net sales declined 5% to $6.72 billion, even after including the GOJO acquisition's positive impact. Organic sales dropped 13% in Q4, with the ERP transition accounting for about 13.5 points of that decline. Gross margin contracted by 520 basis points in Q4 and 290 basis points for the year, landing at 41.3% and 42.3% respectively. Diluted EPS was cut in half in Q4, falling to $1.34, and dropped 26% for the year to $4.81. Adjusted EPS also declined sharply. Net cash from operations fell 38% year-over-year, from $981 million to $612 million. Segment data shows double-digit declines in Household and Lifestyle, with only the Health and Wellness and International segments posting growth, largely due to the GOJO acquisition. The data is detailed for headline metrics but lacks granularity on acquisition costs and capital intensity.

Analysis

The announcement is a factual disclosure of quarterly and annual results, with all key claims supported by numerical data. The tone is neutral, and there is no evidence of narrative inflation or exaggerated language. The results show a clear deterioration in financial performance: net sales, gross margin, EPS, and cash flow all declined year-over-year, even after accounting for the GOJO acquisition. There are no forward-looking claims in the summary or key claims, and the only capital-intensive event (the GOJO acquisition) is reported as completed, with its impact on sales quantified. No language attempts to reframe negative results as positive, and there are no aspirational or promotional statements. The gap between narrative and evidence is minimal; the data fully supports the claims made.

Risk flags

• ●Profitability risk is acute, as gross margin fell by 520 basis points in Q4 and 290 basis points for the year, indicating that cost pressures and negative mix are eroding earnings power. This matters because margin compression directly impacts the company's ability to generate profit and reinvest.
• ●Cash flow risk is material, with net cash provided by operations dropping 38% year-over-year to $612 million. Sustained declines in operating cash flow can constrain the company’s flexibility to fund investments, pay down debt, or return capital to shareholders.
• ●Disclosure risk is present due to the lack of detailed information on the GOJO acquisition cost, capital expenditures, and geographic sales. This omission limits investors' ability to assess the true capital intensity and regional performance, making it harder to evaluate long-term value creation.

Bottom line

Clorox's latest results show a company under pressure: sales, margins, earnings, and cash flow all declined, even after factoring in the boost from the GOJO acquisition. The headline numbers are transparent and the company does not attempt to spin the negative trends, but the lack of detail on acquisition costs and capital spending leaves key questions unanswered. With profitability and cash generation both deteriorating, the core narrative is credible but not reassuring. There is no evidence of near-term turnaround or hidden upside in these disclosures. For investors, the most important takeaway is that Clorox's operational and cost challenges are real and immediate, and the GOJO acquisition has not offset the underlying weakness. Further disclosure on capital allocation and integration progress would be needed to reassess the outlook.

Announcement summary

(NYSE: CLX) The Clorox Company reported fourth quarter and fiscal year 2026 results, with net sales for Q4 decreasing 2% to $1.95 billion and net sales for the full year decreasing 5% to $6.72 billion. In April 2026, the company completed the acquisition of GOJO Industries, Inc., which added about 10 points to Q4 net sales and about 3 points to full-year net sales. Gross margin for Q4 decreased 520 basis points to 41.3%, and for the full year decreased 290 basis points to 42.3%. Diluted EPS for Q4 decreased 50% to $1.34, and for the full year decreased 26% to $4.81, while adjusted EPS for Q4 decreased 42% to $1.66 and for the full year decreased 28% to $5.53. Net cash provided by operations was $612 million compared to $981 million in fiscal year 2025, representing a 38% decrease. The company expects net sales for fiscal year 2027 to be up 13% to 14%, with diluted EPS projected between $5.41 and $5.71 and adjusted EPS between $5.70 and $6.00. Clorox's global health and hygiene portfolio now represents more than half of net sales.

Disagree with this article?